Menu Search
Equities

Catalent Inc

CTLT:NYQ

Catalent Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.66
  • Today's Change0.66 / 1.12%
  • Shares traded1.19m
  • 1 Year change+49.75%
  • Beta1.1480
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Catalent Inc's net income fell 307.42% from a loss of 256.00m to a larger loss of 1.04bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 75.60% to 78.25%.
Gross margin21.82%
Net profit margin-9.34%
Operating margin-2.04%
Return on assets-4.19%
Return on equity-11.19%
Return on investment-4.80%
More ▼

Cash flow in USDView more

In 2024, Catalent Inc did not generate a significant amount of cash. However, the company earned 268.00m from its operations for a Cash Flow Margin of 6.12%. In addition the company generated 74.00m cash from financing while 327.00m was spent on investing.
Cash flow per share0.4237
Price/Cash flow per share140.64
Book value per share19.57
Tangible book value per share2.02
More ▼

Balance sheet in USDView more

Catalent Inc has a Debt to Total Capital ratio of 58.21%, a lower figure than the previous year's 112.52%.
Current ratio2.51
Quick ratio1.93
Total debt/total equity1.39
Total debt/total capital0.5821
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -307.42%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		59.47
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.